- Home
- EVG vs ALEC Comparison
EVG vs ALEC Comparison
Compare EVG & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
EVG
Eaton Vance Short Diversified Income Fund Eaton Vance Short Duration Diversified Income Fund of Beneficial Interest
Current Price
Company Overview
Basic Information| Metric | EVG | ALEC |
|---|---|---|
| Founded | 2005 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 148.1M | 193.2M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | EVG | ALEC |
|---|---|---|
| Price | $11.01 | $1.82 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $3.33 |
| AVG Volume (30 Days) | 49.4K | ★ 1.3M |
| Earning Date | 01-01-0001 | 02-25-2026 |
| Dividend Yield | ★ 8.68% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $69,048,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $155.87 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 12.26 |
| 52 Week Low | $9.13 | $0.87 |
| 52 Week High | $10.86 | $3.40 |
Technical Indicators
Market Signals| Indicator | EVG | ALEC |
|---|---|---|
| Relative Strength Index (RSI) | 52.80 | 68.76 |
| Support Level | $10.94 | $1.50 |
| Resistance Level | $11.09 | $1.87 |
| Average True Range (ATR) | 0.07 | 0.09 |
| MACD | 0.02 | 0.05 |
| Stochastic Oscillator | 63.46 | 88.30 |
Price Performance
Historical ComparisonAbout EVG Eaton Vance Short Diversified Income Fund Eaton Vance Short Duration Diversified Income Fund of Beneficial Interest
Eaton Vance Short Duration Diversified Income Fund is a diversified, closed-end management investment company. Its primary investment objective is to provide a high level of current income with a secondary objective of seeking capital appreciation to the extent consistent with its primary goal. The portfolio of investments consists of business equipment and services, automotive, cable and satellite television, chemicals and plastics, food products, and other areas.
About ALEC Alector Inc.
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.